EUROMALDI

Ultra high performance MALDI mass spectrometer for basic research use and clinical applications

 Partecipanti

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Mass spectrometry is an analytical science covering the multiple fields of chemistry, physics and biology. Each world has its specific needs and ways of producing and analysing samples. The world of clinical proteomics is complex since it involves a close interaction between doctors and hospital practitioners, not mass spectrometrists by nature, and analytical scientists. Several SMEs already enter the field; however none of the proposed solutions have yet reached the ultimate goal of producing the perfect software suite for clinicians and the right instrument for the challenge of ultimate biomarker discovery. However, this challenge is a never ending story since instrument capabilities to look for a needle in a haystack need to be improved continuously. The present Euro MALDI project aims at developing a new powerful proteomic solution for clinical applications. The proteomic platform will be composed of three main software for lipidomics, protein profiling and tandem mass spectrometry with a clinical interface and a high end MALDI TOF-TOF mass spectrometer. This challenge will be fulfilled by collaboration between academia (UnivMed) and an SME (Kratos). Kratos, a specialist in surface analysis and mass spectrometry ,will install a high end mass spectrometer in the premises of the centre for oncology and oncopharmacology (UnivMed/CRO2). CRO2 groups basic and clinical research teams as well as hospital practitioners. The centre has several core facilities such as technological platforms, biobanks, and animal nursing. Moreover the centre has its own research team in proteomics. CRO2 will provide the necessary expertise in clinical biology and biological mass spectrometry to optimize the MALDI mass spectrometer and allow its commercial release by the end of the project. This will lead to long term collaboration between UnivMEd and Kratos with wide social, societal and economic benefits.'

Introduzione (Teaser)

A very powerful platform that exploits mass spectrometry (MS) to simultaneously identify biologically relevant proteins, lipids and carbohydrates could change the face of clinical medicine.

Descrizione progetto (Article)

MS identifies the type and amount of a substance present in an ionised sample by separation according to mass and charge. The analytical technique has shed important light on the nature of materials and samples in a variety of fields, with significant application in the field of proteomics. However, the ultimate tool for biomarker identification via clinical proteomics has remained elusive.

Biomolecules tend to be fragile and fragment when ionised. Matrix-assisted laser desorption/ionisation (MALDI) is a so-called soft ionisation technique whose processes are less harsh and more suitable to biological samples. MALDI MS can measure multiple analytes directly from intact tissues, including clinical samples, without the need for target-specific reagents. The EU-funded project 'Ultra high performance MALDI mass spectrometer for basic research use and clinical applications' (http://iappeuromaldi.com/ (EUROMALDI)) was launched to produce a pioneering proteomics platform.

The partnership joins a United Kingdom global industry leader in MALDI MS with a French university research consortium of six different teams from academics, a hospital, and the French National Institute of Health and Medical Research (INSERM). Scientists are optimising MALDI MS instrumentation designed by the United Kingdom company to enable high-resolution, high-throughput analysis of proteins, lipids and carbohydrates for clinical applications. The prototype will address two of the most deadly carcinomas: glioblastoma (a highly invasive type of malignant brain and spinal cord tumour) and pancreatic cancer.

Within the first reporting period, researchers have made excellent progress. The team will implement tandem MS involving at least two stages of mass analysis. Researchers are developing cutting-edge software for tandem MS and lipidomics. All planned software components are either in testing or prototype phase, and the capabilities of the new MALDI MS platform already exceed initial expectations.

The industry-academic partnership behind the successful EUROMALDI project will enhance the market position of the company while bringing important investments to the academic research consortium thanks to enhanced global standing. Needless to say, the ability to identify in real time in the clinic a range of protein, lipid and carbohydrate molecules associated with diseases will revolutionise diagnosis, prevention and treatment.